Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

128.61 +3.54 (+2.83%)
Streaming Delayed Price Updated: 1:45 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Does GENEDX HOLDINGS CORP (NASDAQ:WGS) align with Mark Minervini’s trading strategy?
A fundamental and technical analysis of (NASDAQ:WGS): Why the high growth investor may take a look at GENEDX HOLDINGS CORP (NASDAQ:WGS). 
Via Chartmill
Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies
From GeneDx
Via Business Wire
GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting
From GeneDx
Via Business Wire
GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis
From GeneDx
Via Business Wire
SPY Trying To Find A Floor At The 200 SMA; One New Swing
In this video lesson I review the day-one of a new rally attempt in the overall market, discuss my new swing trade in a cyber-security leader, and review my tier-one long-term portfolio purchases in my... 
Via Talk Markets
Topics Stocks / Equities
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication
From GeneDx
Via Business Wire
Powerful UnR Session As All Four Market Indices Lockstep Rally Into The Close; Bear Trap Set?
In this video lesson, I review the overall market, the recent bearish sentiment, and one new swing trade idea for Monday's session. 
Via Talk Markets
Topics Stocks / Equities
Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols
From GeneDx
Via Business Wire
Top Biotech GeneDx Catapults 42% After Obliterating Earnings Forecasts
GeneDx stock catapulted more than 40% on Tuesday after the top-notch biotech smashed fourth-quarter expectations. 
Via Investor's Business Daily
Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings
 
Via Benzinga
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday?
Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
From GeneDx
Via Business Wire
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Earnings Scheduled For February 18, 2025
 
Via Benzinga
GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
From GeneDx
Via Business Wire
GeneDx to Participate in 45th Annual TD Cowen Health Care Conference
From GeneDx
Via Business Wire
GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
From GeneDx
Via Business Wire
GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025
From GeneDx
Via Business Wire
GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play
Saying shares of GeneDx skyrocketed in 2024 may be an understatement. As a leader in its market, upside is still a legitimate possibility for this name. 
Via MarketBeat
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
Stocks Moving Lower Despite Encouraging Inflation Data
Via Talk Markets
Topics Economy Stocks / Equities
GeneDx Announces Preliminary 2024 Financial Results
From GeneDx
Via Business Wire
GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers
From GeneDx
Via Business Wire
I’m Not Worried About This Pullback
Stocks gave back all of Monday’s gains and then some today. Monday’s panic buyers were mercilessly punished for going nuts during the spree. 
Via Talk Markets
Topics Cryptocurrencies Stocks / Equities
GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
From GeneDx
Via Business Wire
IBD 50's GeneDx Surges On FDA Recommendations For AI Device Development
GeneDx provides whole and exome gene sequencing to identify rare diseases. 
Via Investor's Business Daily
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.